EUVIMEDOpdag EUVIMED
Systematische ÜbersichtMetaanalyseOpen access · CC BY-NC 3.0

Real-World Effectiveness of Triple Extrafine Fixed-Dose Combination with Beclomethasone/Formoterol/Glycopyrronium on Symptoms and Lung Function in COPD: A Systematic Review and Meta-Analysis

Paola Rogliani iD, Gian Marco Manzetti iD, Mario Cazzola iD, Luigino Calzetta iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025-05 · Volume 20 · 1723-1736

DOI: 10.2147/copd.s511334 ↗

At a glance

Systematische Übersicht in International Journal of Chronic Obstructive Pulmonary Disease, 2025-05. Written by Paola Rogliani and 3 co-authors. Institution: Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. Major MEDLINE topics: Adrenergic beta-2 Receptor Agonists, Anti-Inflammatory Agents, Beclomethasone, Formoterol Fumarate. Cited 7 times so far (Crossref); 86 references. The full text is freely available (open access, CC BY-NC 3.0). Funded by: Chiesi Italia S.p.A..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Chronic obstructive pulmonary disease (COPD) is a significant global health issue characterized by persistent airflow limitation and inflammation. Triple fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS), long-acting β2-agonists (LABA), and long-acting muscarinic antagonists (LAMA) show promise by potentially enhancing bronchodilation and anti-inflammatory effects. Although randomized controlled trials (RCTs) provide efficacy data, they may not fully represent real-world clinical practice, highlighting the value of real-world evidence (RWE).

Methods

This study conducted a systematic review and meta-analysis of prospective observational multicenter studies to evaluate the real-world effectiveness of a triple extrafine FDC containing beclomethasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G) in moderate-to-severe COPD patients. Databases MEDLINE and SCOPUS were searched for relevant studies reporting on the COPD Assessment Test (CAT) score and forced expiratory volume in one second (FEV1).

Results

The meta-analysis included seven studies with 5952 patients, indicating high methodological quality with Newcastle-Ottawa Scale scores ≥7. Results showed significant improvement in CAT scores (-5.82 95% CI -7.61 - -4.03; P < 0.001) and FEV1 (127 mL 95% CI 42-212; P < 0.001) for extrafine BDP/FF/G FDC compared to any prior treatments (ICS/LABA, ICS+LABA, LABA/LAMA, LABA+LAMA, multiple-inhaler triple therapy, single-inhaler triple therapy), exceeding minimal clinically important differences. Heterogeneity was significant, but Egger's test suggested no significant publication bias.

Conclusion

The triple extrafine BDP/FF/G FDC effectively improves health status and lung function in real-world COPD patients, supporting its use as a viable therapeutic strategy. Further research should explore long-term outcomes and investigate specific patient subgroups to optimize individualized treatment approaches.

Subjects

MeSH terms (MEDLINE)

Adrenergic beta-2 Receptor AgonistsAnti-Inflammatory AgentsBeclomethasoneFormoterol FumarateGlucocorticoidsGlycopyrrolatePulmonary Disease, Chronic ObstructiveAgedFemaleHumansMaleMiddle AgedAdministration, InhalationBronchodilator AgentsDrug CombinationsForced Expiratory VolumeLungMuscarinic AntagonistsObservational Studies as TopicRecovery of FunctionSeverity of Illness IndexTreatment Outcome

Author keywords

COPDlung functionmeta-analysisreal-world evidencesymptoms

Substances

Adrenergic beta-2 Receptor AgonistsAnti-Inflammatory AgentsBeclomethasoneBronchodilator AgentsDrug CombinationsFormoterol FumarateGlucocorticoidsGlycopyrrolateMuscarinic Antagonists

Authors and institutions

  • Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.
  • Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

ORCID profiles: Paola Rogliani, Gian Marco Manzetti, Mario Cazzola, Luigino Calzetta

Funding

  • Chiesi Italia S.p.A.

Cite

APA

Rogliani, P., Manzetti, G. M., Cazzola, M., & Calzetta, L. (2025). Real-World Effectiveness of Triple Extrafine Fixed-Dose Combination with Beclomethasone/Formoterol/Glycopyrronium on Symptoms and Lung Function in COPD: A Systematic Review and Meta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease, Volume 20, 1723-1736. https://doi.org/10.2147/copd.s511334

Vancouver

Rogliani P, Manzetti GM, Cazzola M, Calzetta L. Real-World Effectiveness of Triple Extrafine Fixed-Dose Combination with Beclomethasone/Formoterol/Glycopyrronium on Symptoms and Lung Function in COPD: A Systematic Review and Meta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2025;Volume 20:1723-1736. doi:10.2147/copd.s511334

BibTeX
@article{Rogliani2025,
  author = {Rogliani, Paola and Manzetti, Gian Marco and Cazzola, Mario and Calzetta, Luigino},
  title = {Real-World Effectiveness of Triple Extrafine Fixed-Dose Combination with Beclomethasone/Formoterol/Glycopyrronium on Symptoms and Lung Function in COPD: A Systematic Review and Meta-Analysis},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  volume = {Volume 20},
  pages = {1723--1736},
  doi = {10.2147/copd.s511334}
}
Start for free →